Condition: Gastric Cancer · Gastroesophageal-junction Cancer · Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
The purpose of this study is to evaluate the efficacy of Tislelizumab in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma. The primary study hypotheses are that: Neoadjuvant and adjuvant Tislelizumab plus chemoradiotherapy, followed by adjuvant Tislelizumab and chemotherapy is superior to neoadjuvant chemoradiotherapy or chemotherapy, followed by adjuvant chemotherapy in terms of rate of Pathological Complete Response (pathCR) at the time of surgery.
This description comes directly from the study's public registry record.
Jia Wei, MD · 0086-025-83304616 · jiawei99@nju.edu.cn
Always discuss trial participation with your own doctor first.
| Wuhan Tongji Hospital | Wuhan, Hubei, China | Not Yet Recruiting |
| Nanjing Drum Tower Hospital | Nanjing, Jiangsu, China | Recruiting |
| Shanxi Province Cancer Hospital | Taiyuan, Shanxi, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05687357